Wolfgang Liedtke, MD, PhD, Senior Vice President, Global Head of Neurology, is a board-certified neurologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines in a broad range of CNS diseases, including genetic medicines and global therapeutic development. Most recently, he was Chair of Neurology at Regeneron, where he oversaw the integration of discovery into 45 clinical trials (14 Phase 3 studies). As a renowned physician-scientist, Dr. Liedtke has a proven track record of successfully conducting late-stage development programs, exemplified by his leadership in completing a CNS clinical trial with more than 11,000 patients, and his contributions to successful late-stage trials of dupilumab. He brings to Anavex deep expertise in neurodegeneration, pain research and translational neuroscience, combined with authorship of 160+ peer-reviewed publications, yielding a current h-index of 82. Dr. Liedtke established the Duke Pain Research Group and founded two pain-focused clinics at Duke University Medical Center, providing clinical care for more than 5,000 patients. He was elected to the Medical Advisory Board of the U.S. Facial Pain Association where he is Lead Neurologist. Prior to Duke University, Dr. Liedtke was an Assistant Professor at The Rockefeller University, where he discovered the TRPV4 ion channel, relevant to neuroinflammation and pain, and is critically involved in TRPV4 channelopathy hereditary disorders, including motor neuropathies. In addition to his TRPV4 discovery he also made key discoveries on gene regulation of the KCC2 neuronal chloride transporter, relevant for neurodevelopmental disorders, including pathologic pain, neural anti-aging and neuroprotection. Dr. Liedtke’s profound translational expertise is highlighted by his works as a lead inventor on numerous U.S. patents and his recent election into the elite American Clinical and Climatological Association (ACCA).